|
|
|
|
|
Norfloxacin
drug data and news
Norfloxacin drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
|
| Generic name | Norfloxacin | ||
| Brand Names/Synonyms | Noroxin (TN); Norfloxacin (JP14/USP); Chibroxin; Noroxin | ||
| Indication | For the treatment of urinary tract infection | ||
| Sponsored links | Description | Not Available | |
| Pharmacology | Norfloxacin is a quinolone/fluoroquinolone antibiotic. Norfloxacin is bactericidal and its mode of action depends on blocking of bacterial DNA replication by binding itself to an enzyme called DNA gyrase, which allows the untwisting required to replicate one DNA double helix into two. Notably the drug has 100 times higher affinity for bacterial DNA gyrase than for mammalian. | ||
| Mechanism Of Action | The bactericidal action of Norfloxacin results from inhibition of the enzymes topoisomerase II (DNA gyrase) and topoisomerase IV, which are required for bacterial DNA replication, transcription, repair, and recombination. Norfloxacin is a broad-spectrum antibiotic that is active against both gram-positive and gram-negative bacterias. The fluorine atom at the 6 position increases potency against gram-negative organisms, and the piperazine moiety at the 7 position is responsible for anti-pseudomonal activity | ||
| Norfloxacin News (When available) |
Chemists volunteer to take a lesser margin Feb 22, 2006 Vitamins, asthma drugs, antibiotics set to be cheaper Sep 19, 2005 Govt slashes prices of 15 bulk drugs Sep 19, 2005 NPPA FIXES/REVISES THE PRICES OF 308 FORMULATION PACKS Sep 19, 2005 India makes bulk drugs cheaper Sep 20, 2005 Many meds don't mix with the sun Sep 21, 2005 Patents Symposium concludes Aug 22, 2005 SICK PSUS COME TO RESCUE OF MUMBAI Aug 18, 2005 GSK India pulls out unprofitable drug Jul 19, 2005 Essential drug not available in Mumbai Jul 15, 2005 Govt cuts prices of pain killers, ulcer drugs, antibiotics Jun 19, 2005 Prices of pain killers, ulcer drugs and antibiotics slashed Jun 19, 2005 NPPA revises bulk drug prices Jun 21, 2005 NPPA revises prices of bulk drugs Jun 21, 2005 NPPA fixes prices of scheduled bulk drugs Jun 21, 2005 NPPA revamps bulk drugs prices Jun 21, 2005 NPPA revises prices of bulk drugs Jun 21, 2005 Govt cuts prices of pain killers, ulcer drugs, antibiotics Jun 19, 2005 Prices of pain killers, ulcer drugs and antibiotics slashed Jun 19, 2005 NPPA revises bulk drug prices Jun 21, 2005 NPPA revises prices of bulk drugs Jun 21, 2005 NPPA fixes prices of scheduled bulk drugs Jun 21, 2005 NPPA revamps bulk drugs prices Jun 21, 2005 NPPA revises prices of bulk drugs Jun 21, 2005 Usefulness of routine analysis of ascitic fluid at the time of ... Mar 30, 2005 Indian bulk drug suppliers lose pricing appeal Apr 11, 2005 The History of Antibiotics Apr 6, 2005 Capital disease: 97 pc resistance to antibiotics Apr 12, 2005 Antibiotics flushed into waterways Mar 16, 2005 | ||
| Dosage Forms | Tablet; solution | ||
| Drug_Category | Anti-Infectives; Enzyme Inhibitors; Quinolones; ATC:J01MA06; ATC:S01AX12 | ||
| Absorption | rapid | ||
| Interactions | Interactions for Norfloxacin: Elevated plasma levels of theophylline have been reported with concomitant quinolone use. There have been reports of theophylline-related side effects in patients on concomitant therapy with norfloxacin and theophylline. Therefore, monitoring of theophylline plasma levels should be considered and dosage of theophylline adjusted as required. Elevated serum levels of cyclosporine have been reported with concomitant use of cyclosporine with norfloxacin. Therefore, cyclosporine serum levels should be monitored and appropriate cyclosporine dosage adjustments made when these drugs are used concomitantly. Quinolones, including norfloxacin, may enhance the effects of oral anticoagulants, including warfarin or its derivatives or similar agents. When these products are administered concomitantly, prothrombin time or other suitable coagulation tests should be closely monitored. The concomitant administration of quinolones including norfloxacin with glyburide (a sulfonylurea agent) has, on rare occasions, resulted in severe hypoglycemia. Therefore, monitoring of blood glucose is recommended when these agents are co-administered. Diminished urinary excretion of norfloxacin has been reported during the concomitant administration of probenecid and norfloxacin. The concomitant use of nitrofurantoin is not recommended since nitrofurantoin may antagonize the antibacterial effect of Norfloxacin in the urinary tract. Multivitamins, or other products containing iron or zinc, antacids or sucralfate should not be administered concomitantly with, or within 2 hours of, the administration of norfloxacin, because they may interfere with absorption resulting in lower serum and urine levels of norfloxacin. Videx (Didanosine) chewable/buffered tablets or the pediatric powder for oral solution should not be administered concomitantly with, or within 2 hours of, the administration of norfloxacin, because these products may interfere with absorption resulting in lower serum and urine levels of norfloxacin. Some quinolones have also been shown to interfere with the metabolism of caffeine. This may lead to reduced clearance of caffeine and a prolongation of its plasma half-life. | ||
| Toxicity | Not Available | ||
| Organisms Affected | Enteric bacteria and other eubacteria | ||
| Chemical IUPAC Name | 1-ethyl-6-fluoro-4-oxo-7-piperazin-1-yl-1H-quinoline-3-carboxylicacid | ||
| Chemical Formula | C16H18FN3O3 | ||
| Molecular Weight | 319.331 g/mol | ||
| Smiles String | CCN1C=C(C(=O)C2=CC(=C(C=C21)N3CCNCC3)F)C(=O)O | ||
| Melting Point | 227-228 °C | ||
| Water Solubility | 1.78E+005 mg/L | ||
| State | Solid | ||
| LogP/Hphobicity | 1.176 | ||
| Isoelectric Point | Not Available | ||
| Biotransformation | via liver and kidney | ||
| Half Life | 3-4 hours | ||
| Protein Binding [%] | 10 and 15% (Serum protein binding) | ||
| RxList Link | RXlist | ||
| Sponsored links | |||
| Drug Reference |
http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/nor1302.shtml http://www.drugs.com/cons/Norfloxacin.html http://www.rxlist.com/cgi/generic3/norfloxacin.htm | ||
| Drug Type | Approved Drug | ||
| Accession No | APRD00469 | ||
| CAS Registry Number | 70458-96-7 | ||
| KEGG Compound ID | C06687 | ||
| PubChem ID | SID:8912 | ||
| PharmGKB ID | PA450654 | ||
| SwissProt ID | Not Available | ||
| GenBank ID | Not Available | ||
| Drug ID Number [DIN] | 2246596 |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |